354 related articles for article (PubMed ID: 33887280)
1. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
5. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
7. Automodified Poly(ADP-Ribose) Polymerase Analysisto Monitor DNA Damagein Peripheral Lymphocytes of Floriculturists Occupationally Exposed to Pesticides.
Imperato S; Mistretta C; Marone M; Migliaccio I; Pulcinelli I; Faraone Mennella MR
Cells; 2019 Feb; 8(2):. PubMed ID: 30744056
[TBL] [Abstract][Full Text] [Related]
8. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose): PARadigms and PARadoxes.
Bürkle A; Virág L
Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
11. Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study.
Rajaee-Behbahani N; Schmezer P; Ramroth H; Bürkle A; Bartsch H; Dietz A; Becher H
Int J Cancer; 2002 Apr; 98(5):780-4. PubMed ID: 11920651
[TBL] [Abstract][Full Text] [Related]
12. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
13. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Redon CE; Nakamura AJ; Zhang YW; Ji JJ; Bonner WM; Kinders RJ; Parchment RE; Doroshow JH; Pommier Y
Clin Cancer Res; 2010 Sep; 16(18):4532-42. PubMed ID: 20823146
[TBL] [Abstract][Full Text] [Related]
14. Sulfoquinovosyl acylpropanediol (SQAP): Inhibition of poly(ADP-ribose) metabolism and enhanced cytotoxicity in homologous recombination repair-deficient Chinese hamster-derived cells.
Maeda J; Shellenberger KD; Kurihara W; Haga T; Kato TA
Mutat Res Genet Toxicol Environ Mutagen; 2023; 892():503703. PubMed ID: 37973295
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors and stratified treatment of prostate cancer.
Lavery A; Gilson C; Chowdhury S
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1213-1215. PubMed ID: 27686597
[No Abstract] [Full Text] [Related]
16. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection.
Luedeman ME; Stroik S; Feng W; Luthman AJ; Gupta GP; Ramsden DA
Nat Commun; 2022 Aug; 13(1):4547. PubMed ID: 35927262
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
